NEW
YORK, July 15, 2022 /PRNewswire/ -- Jakubowitz
Law announces that a securities fraud class action lawsuit has
commenced on behalf of shareholders of Spero Therapeutics, Inc.
(NASDAQ: SPRO).
To receive updates on the lawsuit,
fill out the form:
https://claimyourloss.com/securities/spero-therapeutics-inc-loss-submission-form/?id=29832&from=4
The lawsuit seeks to recover losses for shareholders who
purchased Spero between October 28,
2021 and May 2, 2022.
Shareholders interested in acting as a lead plaintiff
representing the class of wronged shareholders have until
July 25, 2022 to petition the
court. Your ability to share in any recovery doesn't require that
you serve as a lead plaintiff.
According to a filed complaint, Spero Therapeutics, Inc. issued
materially false and/or misleading statements and/or failed to
disclose that: (i) the data submitted in support of the New Drug
Application ("NDA") for the Company's product candidate, Tebipenem
HBr, were insufficient to obtain approval from the U.S. Food and
Drug Administration ("FDA"); (ii) accordingly, it was unlikely that
the FDA would approve the Tebipenem HBr NDA in its current form;
(iii) the foregoing would necessitate a significant workforce
reduction and restructuring of Spero's operations; and (iv) as a
result, the Company's public statements were materially false and
misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities fraud. Attorney
advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/spro-shareholder-alert-jakubowitz-law-reminds-spero-shareholders-of-a-lead-plaintiff-deadline-of-july-25-2022-301587171.html
SOURCE Jakubowitz Law